Mesna in Veterinary Oncology: Uroprotection With Ifosfamide and Cyclophosphamide

mesna (sodium 2-mercaptoethane sulfonate) is covered as protocol-linked uroprotective medicine; not antitumour therapy, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Protocol-linked uroprotective medicine; not antitumour therapy. Mesna.

Mesna.

Mesna binds and inactivates urotoxic oxazaphosphorine metabolites in urine, reducing their contact injury to bladder epithelium. It does not protect against all ifosfamide or cyclophosphamide toxicities.

Merck recommends mesna with fluid diuresis when ifosfamide or high-dose cyclophosphamide is used. It may also be selected for other high-risk cyclophosphamide contexts by the oncologist.

Merck recommends mesna with fluid diuresis when ifosfamide or high-dose cyclophosphamide is used. It may also be selected for other high-risk cyclophosphamide contexts by the oncologist.

Clinic-administered or protocol-directed medicine paired with selected alkylating chemotherapy

Veterinary pharmacology and a retrospective canine comparison support uroprotection, but mesna did not eliminate sterile haemorrhagic cystitis and study design does not prove one prevention strategy is always superior.

Hypersensitivity or gastrointestinal effects can occur, and an incorrect schedule can leave periods of inadequate urinary protection. Mesna does not remove marrow, kidney, neurologic or gastrointestinal toxicity from the chemotherapy agent.

The timing relationship to the alkylator and fluid plan is essential. Mesna must not be added by an owner after treatment without the oncology service.

No FDA-approved canine or feline oncology label was established for mesna in this audit. US veterinary use is extra-label within a veterinarian-directed protocol.

Multi-region extra-label specialist use; availability varies.

The clinic records the chemotherapy exposure, hydration, urination and baseline urinalysis. Caregivers report blood in urine, straining, frequent urination, pain or reduced urine immediately. The oncologist decides whether urinalysis, culture, imaging or permanent drug discontinuation is needed.